Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · Real-Time Price · USD
8.92
+0.77 (9.45%)
At close: Feb 6, 2026, 4:00 PM EST
8.88
-0.04 (-0.47%)
After-hours: Feb 6, 2026, 7:59 PM EST
Relay Therapeutics Revenue
Relay Therapeutics had revenue of $8.36M in the twelve months ending September 30, 2025, down -16.50% year-over-year. In the year 2024, Relay Therapeutics had annual revenue of $10.01M, down -60.83%.
Revenue (ttm)
$8.36M
Revenue Growth
-16.50%
P/S Ratio
181.61
Revenue / Employee
$44,441
Employees
188
Market Cap
1.55B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.01M | -15.54M | -60.83% |
| Dec 31, 2023 | 25.55M | 24.17M | 1,749.82% |
| Dec 31, 2022 | 1.38M | -1.65M | -54.41% |
| Dec 31, 2021 | 3.03M | -79.63M | -96.34% |
| Dec 31, 2020 | 82.65M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.76B |
| Novavax | 1.06B |
| Monte Rosa Therapeutics | 181.54M |
| AnaptysBio | 169.47M |
| Intellia Therapeutics | 57.53M |
| DBV Technologies | 5.50M |
| AtaiBeckley | 3.02M |
| Upstream Bio | 2.80M |
RLAY News
- 2 days ago - Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 4 days ago - Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer - GlobeNewsWire
- 10 days ago - Oppenheimer Upgrade Fuels Relay Therapeutics Rally On Zovegalisib Optimism - Seeking Alpha
- 2 months ago - Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 - GlobeNewsWire
- 2 months ago - Relay Therapeutics, Inc. (RLAY) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 3 months ago - Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates - GlobeNewsWire
- 3 months ago - Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November - GlobeNewsWire
- 3 months ago - Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025 - GlobeNewsWire